The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Regulatory News (NFX)

Share Price Information for Nuformix (NFX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.19
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.02 (11.111%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 0.19
NFX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

28 Sep 2018 10:09

RNS Number : 3235C
Nuformix PLC
28 September 2018
 

 

28 Setember 2018

Nuformix plc

("Nuformix" or the "Company")

 

PDMR

 

The Company was notified on 28 September 2018 that Kirk Siderman-Wolter, Non-Executive Director of the Company, bought 35,364 Nuformix plc ordinary shares of 0.1p each ("Shares") at a purchase price of 2.6p per share.

 

Following this transaction he holds 35,364 shares, representing 0.00077% of the issued share capital of the Company.

1

 

Details of the person discharging managerial responsibilities.

 

a)

 

Name

 

 

Kirk  Siderman-Wolter

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-Executive Director

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Nuformix plc

b)

 

LEI

 

 

2138003XG3H3I2J3BJ24

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 0.1p each

Identification code

GB00BYW79Y38

b)

 

Nature of the transaction

 

 

Acquisition of ordinary Shares

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

2.6p

35,364

d)

 

Aggregated information

- Aggregated volume

35,364

- Price

2.6p

e)

 

Date of the transaction

 

 

16.08.18

f)

 

Place of the transaction

 

 

Standard List, London Stock Exchange

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHPGURUBUPRUBR
Date   Source Headline
15th Jan 202012:43 pmRNSAmendment to Notice
10th Jan 202011:45 amRNSIssue of Equity
8th Jan 20208:17 amRNSHolding(s) in Company
24th Dec 20197:00 amRNSHalf-year Report
25th Nov 20194:41 pmRNSSecond Price Monitoring Extn
25th Nov 20194:36 pmRNSPrice Monitoring Extension
25th Nov 20197:00 amRNSUpdate and Placing Announcement
28th Oct 20192:05 pmRNSSecond Price Monitoring Extn
28th Oct 20192:00 pmRNSPrice Monitoring Extension
28th Oct 20198:30 amRNSIssue of Equity
25th Oct 201911:11 amRNSStatement re. Share Price Movement
25th Oct 20199:05 amRNSSecond Price Monitoring Extn
25th Oct 20199:00 amRNSPrice Monitoring Extension
20th Sep 20192:05 pmRNSSecond Price Monitoring Extn
20th Sep 20192:00 pmRNSPrice Monitoring Extension
10th Sep 20194:49 pmRNSAGM Results
10th Sep 20197:00 amRNSDirectorate Change
9th Sep 20197:00 amRNSEbers Cannabinoid Collaboration Update
6th Sep 20197:30 amRNSAppointment of Dr Muhunthan Thillai
4th Sep 20197:30 amRNSHolding(s) in Company
1st Aug 20199:30 amRNSAnnual Financial Report
29th Jul 20197:00 amRNSHolding(s) in Company
18th Jul 20197:00 amRNSFinal Results
7th Jun 20197:00 amRNSHolding(s) in Company
6th Jun 20197:00 amRNSHolding(s) in Company
30th May 201911:05 amRNSSecond Price Monitoring Extn
30th May 201911:00 amRNSPrice Monitoring Extension
30th May 20197:01 amRNSPositive Results for NXP001 Clinical Trial
28th May 20197:00 amRNSHolding(s) in Company - Amendment
24th May 20197:30 amRNSHolding(s) in Company
24th May 20197:00 amRNSLoan Conversion
22nd May 20197:00 amRNSHolding(s) in Company
22nd May 20197:00 amRNSHolding(s) in Company
22nd May 20197:00 amRNSHolding(s) in Company
15th May 20194:40 pmRNSSecond Price Monitoring Extn
15th May 20194:35 pmRNSPrice Monitoring Extension
15th May 20197:00 amRNSNuformix Achieves 2nd NXP001 Development Milestone
10th May 20199:00 amRNSPrice Monitoring Extension
8th May 20197:30 amRNSHolding(s) in Company
9th Apr 20197:00 amRNSStrategic Cannabinoid Agreement
5th Apr 20197:00 amRNSNotification Major Share Interests
22nd Mar 20197:00 amRNSNuformix Commences NXP001 Clinical Trial
27th Feb 20197:00 amRNSMHRA approval for NXP001
20th Feb 20196:16 pmRNSHolding(s) in Company
20th Dec 20187:00 amRNSUnaudited Half Year Results
3rd Dec 20187:00 amRNSReports Results from Novel IPF Pre-Clinical Trial
27th Nov 20187:00 amRNSExpansion of NXP001 Agreement & Milestone Payment
28th Sep 201810:09 amRNSDirector/PDMR Shareholding
28th Sep 20187:00 amRNSAdditional New NXP002 Patent Filing
19th Sep 20182:33 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.